Salix (SLXP) December volatility at 56, January at 68, April at 73 into PDUFA
More News related to SLXP
- Salix Pharma (SLXP) Posts Q4 Loss of $0.13, Narrower than Views; Guides FY10 and Q110 EPS
- Salix Pharmaceuticals Reports 4Q2009 and FY2009 Results
- Trading Radar for 03/09: Kroger (KR), Dick's Sporting Goods (DKS), Stage Stores (SSI), J. Crew (JCG), Thor Industries (THO) Report
- Unusual 11 Mid-Day Movers 2/24: PSID, BNE, FFCO, SLXP, VOCL Higher; STEC, CIMT, CFI, TA Lower
- Notable Analyst Rating Changes 02/24: XCO, FPL, SLXP, EOG, ADSK Upgraded; STEC, APA, KND Downgraded
More News related to FDA
- Medtronic (MDT) Announces Initial Results of STOP AF Clinical Trial - All Primary Endpoints Met
- BioDelivery Sciences (BDSI) Announces Positive BEMA Granisetron Meeting with U.S. FDA
- PharmAthene (PIP) Suspends Work on SparVax Development
- Medtronic's (MDT) Revo MRI SureScan Gets Approval With Conditions from U.S. FDA
- Simcere Pharma (SCR) Announces Completion of Endostar Phase IV
Salix Pharmaceutical (Nasdaq: SLXP) is recently trading up 91c to $22.91. The PDUFA for rifaximin, treatment for hepatic encephalopathy (HE), is March 24, 2010. SLXP December option implied volatility is at 56, January is at 68, April is at 75; verses its six-month average of 73 according to Track Data. Paul Foster
Related Categories
FDAOptions
Stocks Mentioned
-0.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
